| Literature DB >> 30420631 |
Anish Pandey1, David W Cleary2,3,4, Jay R Laver2, Andrew Gorringe5, Alice M Deasy6,7, Adam P Dale2,3, Paul D Morris6,7, Xavier Didelot8,9, Martin C J Maiden10, Robert C Read11,12,13.
Abstract
Neisseria lactamica is a harmless coloniser of the infant respiratory tract, and has a mutually-excluding relationship with the pathogen Neisseria meningitidis. Here we report controlled human infection with genomically-defined N. lactamica and subsequent bacterial microevolution during 26 weeks of colonisation. We find that most mutations that occur during nasopharyngeal carriage are transient indels within repetitive tracts of putative phase-variable loci associated with host-microbe interactions (pgl and lgt) and iron acquisition (fetA promotor and hpuA). Recurrent polymorphisms occurred in genes associated with energy metabolism (nuoN, rssA) and the CRISPR-associated cas1. A gene encoding a large hypothetical protein was often mutated in 27% of the subjects. In volunteers who were naturally co-colonised with meningococci, recombination altered allelic identity in N. lactamica to resemble meningococcal alleles, including loci associated with metabolism, outer membrane proteins and immune response activators. Our results suggest that phase variable genes are often mutated during carriage-associated microevolution.Entities:
Mesh:
Year: 2018 PMID: 30420631 PMCID: PMC6232127 DOI: 10.1038/s41467-018-07235-5
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919
Phase-variable locus mutations observed in comparison of in vitro passage and in vivo colonization during short-term carriage (1 month)
| Position | Common genotypesa | In vivo only genotypes | Locationb | Gene/(s) | Details |
|---|---|---|---|---|---|
| 1,483,216 | (G)10→9 | (G)10→11 | Coding | NEIS1156 (c-hp) | Glycosyl transferase |
| 161,341 | (C)12→13 | (C)12→11 | Coding | NEIS2011 ( | LOS subunit modifierby transferase activity |
| 1,124,158 | (G)9→10 | (TACGCTGGAAGC)1–2 | Coding | NEIS2362(36) | Type I restriction modification system, specificity subunit S |
| 1,124,237 | (G)9→10 | (G)9→11 | Coding | NEIS2362(36) | Type I restriction modification system, specificity subunit S |
| 1,483,216 | N/A: in vivo only | (C)10→11 | Coding | glycosyl transferase family 2 | Glycosyl transferase gene |
| 617,862 | N/A: in vivo only | (C)10→9 | Coding |
| Haemoglobin-haptoglobin utilisation protein |
| 1,688,136 | N/A: in vivo only | (G)13 →12 | Intergenic | l-hp/rubredoxin | Large multidomain proteinc/Rubredoxin: involved in Fe2+ binding |
| 1,717,988 | N/A: in vivo only | (C)10→9 | Intergenic | DNA binding protein /multidomain protein | |
| 1,933,087 | (A)28→27 | (A)28→26 | Intergenic | AutA /hp | Autotransporter A |
| 593,527 | (G)10→9 | (G)10→12 | Intergenic | FetA VRF4-8 ←/→ NEIS1949 | Finetyping antigen/GroS chaperone protein folding |
| 189,023 | (A)20→19 | (A)20→17 | Intergenic | NEIS2043: 2 (Thif) →/← NEIS2044: 28 | Enzyme activation/hp |
| 837,301 | (CTTG)9→10 | (CTTG)9→11 | Intergenic | hp ←/→ NEIS0842:42 | YadA-like C-terminal region/conserved hypothetical protein |
| 893,705 | (T)18→17 | (T)18→15 | Intergenic | NEIS0978 (396) ←/← NEIS0528(112) | Putative surface fibrial protein/putative periplasmic binding protein |
| 893,707 | (T)18→17 | (T)18→19 | Intergenic | NEIS0978 (396) ←/← NEIS0528(112) | Putative surface fibrial protein/putative periplasmic binding protein |
aCommon genotypes are those that were found in both in vivo and in vitro datasets
bLocations are wither within coding sequences or intergenic. For the latter this simply refers to a location outside a known CDS, no inference to upstream promoters has been made
cMulti Domain Protein contained the following domains (yadA Hia auto transporter, chromosome segregation ATPase, flagellin)
Effective population size and Tajima’s D calculated for N. lactamica Y92–1009 sample sets
| Tajima's D | Effective population size ( | ||
|---|---|---|---|
| In vitro passaged ( | −1.08 | 0.13 (+/−0.11) | 18.74 |
| In vivo ( | −0.92 | 0.12 (+/−0.12) | 17.52 |
| In vivo | −1.02 | 0.20 (+/−0.18) | 29.79 |
| In vivo | −0.96 | 0.26 (+/−0.23) | 39.10 |
Sample sets marked with
aWere sourced from a short-term clinical study in which isolates were recovered from inoculated volunteers as opposed to in vitro passage. This study took place over a month. Sample sets marked with
bWere sourced from a long-term, 26-week colonization, experimental human challenge study. S.d. is standard deviation
Fig. 1a, b Mutations that occurred in isolates recovered over 6 months of nasopharyngeal carriage are outlined as follows: changes to repetitive tracts of phase-variable, contingency loci (Red), genes in which SNPs were persistently detected across multiple volunteers (Blue), including an example from the short-term, in vitro VS in vivo study (Green) and the sole gene in which various mutations discovered across multiple timepoints and volunteers (Yellow). m refers to the number of mutations detected in a given gene across v volunteers. The genes are placed in positions relative to their approximate location in the N. lactamica Y92-1009 genome. b Volunteers in which Single-Nucleotide Polymorphisms (SNPs) were seen are specified in the Volunteer column. Mutations which affected multiple volunteers are quantified in the accompanying figure above. Mutation locations are indicated in the Position column. The type of mutation is given in the mutation column where C tract/G tract refers to a homopolymeric region of cytosine/ guanine repeats where insertions and deletions occurred. PV denotes phase-variable
Fig. 2Domains, mutations and mutation areas of effect introduced in Large-Hypothetical Protein (ARB05049.1) (a) with the distribution found between volunteers (b). Mutations are coloured blue and white and are listed in b in the order they occur along the protein depicted in a
Relative recombination effect (r/m) of isolates in colonised volunteers and the parameters used to infer them
| Colonisation | Organism | ST | Isolates ( | R/theta | Deltaa | Nu | r/m |
|---|---|---|---|---|---|---|---|
|
| 613 | 97 | 0.48 (5.7 E−4) | 35 (2.8 E−2) | 0.22 (1.6E−5) | 3.61 | |
| Co-colonised | 613 | 19 | 0.40 (9.1 E−3) | 138 (4.5 E−6) | 0.11 (9.1 E−4) | 3.84 | |
| 11524 | 3 | 0.68 (3.0 E−2) | 585 (2.1 E−7) | 0.05 (6.4 E−6) | 18.06 | ||
| 41 | 3 | 0.38 (1.8 E−3) | 403 (7.4 E−7) | 0.07 (1.2 E−6) | 10.69 | ||
| 4192 | 6 | 0.39 (9.1 E−3) | 123 (3.5 E−6) | 0.19 (1.4 E−4) | 9.21 | ||
| 10457 | 3 | 0.28 (1.2 E−2) | 420 (9.4 E−7) | 0.07 (4.3 E−5) | 8.32 |
The table displays recombination parameters among wild-type (WT) N. lactamica and N. meningitidis in addition to inoculated (I) N. lactamica Y92-1009 in single and co-colonised volunteers. The parameters include the relative rate of recombination to mutation (R/theta), the mean length of detected recombinant regions (Delta) and mean divergence level between recipient and donor (Nu). Standard deviations are indicated for these values in the accompanying brackets (X.X E−). The parameters were multiplied together to generate the relative effect of recombination compared to the relative effect of mutation (r/m). The sequence type (ST) of each collection of organisms is also given
aDelta is calculated by ClonalFrameML as 1/Delta. This has been resolved in the table to show clearly how r/m was calculated. Standard deviations for this value are for 1/Delta
Genes undergoing recombination
| Organism | Volunteer | Recombinant NEIS loci | Gene alias | Annotation | Direction of recombination |
|---|---|---|---|---|---|
| 166 | NEIS1708 | NMB0444 | hp | Unknown | |
| 133 | NEIS1794 | N/A | Putative mafS3 cassette | Unknown | |
| 38 | NEIS1828 | NMB0342 | Intracellular septation protein A | Unknown | |
| 36 | NEIS1795 | NMC1795 | Mafl immunity gene: type o2MGI-2 | Unknown | |
| 291 | NEIS0069 | NMB0085 | Sodium glutamate transport | Unknown | |
| 291 | NEIS0073 | NMB0088 | Outer membrane transport | Unknown | |
| 291 | NEIS1837 | NMB0334 (pgi2) | Glycolysis pathway enzyme | Unknown | |
| 291 | NEIS2437 | NMB0336 | Putative lipoprotein | Unknown | |
| 291 | NEIS0071 | NMB0071 | Putative lipoprotein | Interspecific | |
| 291 | NEIS0072 | NMB0087 | hp | Interspecific | |
| 291 | NEIS0899 | NMB0922 (lst) | LOS alpha-2,3-sialyltransferase | Interspecific | |
| 291 | NEIS2514 | hp | — | Interspecific | |
| 291 | NEIS1834 | NMB0336 | Enoyl-(acyl carrier protein) reductase | Interspecific | |
| 291 | NEIS1835 | NMB0335 | N-succinyltransferase | Interspecific | |
| 36 | NEIS2149 | NMB0011 | Peptidoglycan (cell wall) biosynthesis | Unknown | |
| 36 | NEIS2859 | hp | — | Unknown | |
| 291 | NEIS0210 | NMB0018 (pilE) | Pilus component synthesis | Unknown | |
| 291 | NEIS1402 | hp | — | Unknown |
The table lists genes identified as recombinant in the dataset following analysis by ClonalFrameML. Isolates of N. lactamica are differentiated with the labels wild-type (WT) and artificially-inoculated (I). Gene names are given as found on PubMLST Neisseria (NEIS loci), in addition to more commonly recognised gene aliases. The label interspecific, refers to loci that shared the same recombinant allele with their co-colonising species during the course of the study